LifeStance Health Group’s (LFST) “Overweight” Rating Reiterated at Morgan Stanley

Morgan Stanley reiterated their overweight rating on shares of LifeStance Health Group (NASDAQ:LFST) in a research report sent to investors on Monday, Benzinga reports. The firm currently has a $10.00 price target on the stock.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group increased their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a neutral rating in a research report on Monday, March 4th. Barclays increased their price objective on shares of LifeStance Health Group from $7.00 to $8.00 and gave the company an underweight rating in a research report on Thursday, February 29th. Finally, Jefferies Financial Group increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company a buy rating in a research note on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, LifeStance Health Group presently has a consensus rating of Hold and an average target price of $8.83.

LifeStance Health Group Trading Up 1.0 %

NASDAQ LFST opened at $6.17 on Monday. LifeStance Health Group has a 12 month low of $4.74 and a 12 month high of $9.59. The company has a 50-day moving average of $6.46 and a 200-day moving average of $6.53. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.11 and a quick ratio of 1.11. The company has a market cap of $2.35 billion, a P/E ratio of -12.10 and a beta of 1.34.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, February 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The business had revenue of $280.60 million for the quarter, compared to analyst estimates of $263.14 million. LifeStance Health Group had a negative return on equity of 12.66% and a negative net margin of 17.64%. As a group, equities analysts predict that LifeStance Health Group will post -0.3 earnings per share for the current year.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, insider Danish J. Qureshi sold 12,965 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $5.93, for a total value of $76,882.45. Following the sale, the insider now directly owns 4,911,050 shares in the company, valued at $29,122,526.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Kevin Michael Mullins sold 44,540 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $6.33, for a total transaction of $281,938.20. Following the transaction, the insider now directly owns 4,745,352 shares of the company’s stock, valued at $30,038,078.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Danish J. Qureshi sold 12,965 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $5.93, for a total value of $76,882.45. Following the transaction, the insider now directly owns 4,911,050 shares in the company, valued at $29,122,526.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 245,463 shares of company stock worth $1,786,868. 8.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LFST. DekaBank Deutsche Girozentrale acquired a new position in LifeStance Health Group during the third quarter worth about $34,000. Sunbelt Securities Inc. acquired a new position in LifeStance Health Group during the third quarter worth about $34,000. WESPAC Advisors LLC acquired a new position in shares of LifeStance Health Group in the 3rd quarter valued at $90,000. Stratos Wealth Partners LTD. acquired a new position in shares of LifeStance Health Group in the 4th quarter valued at $93,000. Finally, Assetmark Inc. boosted its position in shares of LifeStance Health Group by 21.6% in the 4th quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock valued at $93,000 after purchasing an additional 2,114 shares during the period. 85.50% of the stock is owned by institutional investors and hedge funds.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.